Ayoola Abidemi Oluyemi

Ayoola Abidemi Oluyemi

Auto-generated profile, based on publicly available information

Ayoola Abidemi Oluyemi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JAJulianah Ore Abiola
Julianah Ore Abiola
AOAyoola Abidemi Oluyemi
Ayoola Abidemi Oluyemi
OIOlajumoke Tolulope Idowu
Olajumoke Tolulope Idowu
OOOluwatoyin Mary Oyinloye
Oluwatoyin Mary Oyinloye
CUChukwudi Ubah
Chukwudi Ubah
BOBabatunji Oyinloye
Babatunji Oyinloye
Currently, there is no known cure for diabetes. Different pharmaceutical therapies have been approved for the management of type 2 diabetes mellitus (T2DM), some are in clinical trials and they have been classified according to their route or mechanism of action. Insulin types, sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, sodium–glucose cotransporter type 2 inhibitors, and incretin-dependent therapies (glucagon-like peptide-1 receptor agonists: GLP-1R, and dipeptidyl peptidase 4 inhibitors: DPP-4). Although some of the currently available drugs are effective in the management of T2DM, the side effects resulting from prolonged use of these drugs remain a serious challenge. GLP-1R agonists are currently the preferred medications to include when oral metformin alone is insufficient to manage T2DM. Medicinal plants now play prominent roles in the management of various diseases globally because they are readily available and affordable as well as having limited and transient side effects. Recently, studies have reported the ability of phytochemicals to activate glucagon-like peptide-1 receptor (GLP-1R), acting as an agonist just like the GLP-1R agonist with beneficial effects in the management of T2DM. Consequently, we propose that careful exploration of phytochemicals for the development of novel therapeutic candidates as GLP-1R agonists will be a welcome breakthrough in the management of T2DM and the co-morbidities associated with T2DM.

3 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
WOWande Michael Oluyemi
Wande Michael Oluyemi
SEShadrach C Eze
Shadrach C Eze
Adeniyi Thompson AdewumiAdeniyi Thompson Adewumi
Adeniyi Thompson Adewumi
FOFaith Osiako
Faith Osiako
YAYemi A. Adekunle
Yemi A. Adekunle
SMSalerwe Mosebi
Salerwe Mosebi
Glucagon-like peptide-1 receptor (GLP-1R) is a focal target in antidiabetic drug discovery. Synthetic non-peptide compounds are routinely employed to investigate GLP-1R, however, scaffolds from natural products will offer us unique structural diversity to design more potent compounds. We investigated the potential of some natural compounds as agonists of GLP-1R. First, we carried out a virtual screening of 244 compounds, from 19 medicinal plants used in antidiabetic traditional medicine, against GLP-1R. We used molecular dynamics simulations, for 200ns, to further investigate the lead five compounds. Binding Free Energies (BFE), Root Mean Square Deviation (RMSD) and other parameters were employed to understand these interactions. Our results showed that lupeol (-57.23) had good BFE (kcal/mol) compared to danuglipron (-56.47), thus demonstrating more robust interactions with GLP-1R. The pocket-buried residues, CYS191 and GLN186, showed strong hydrogen bonds while the critical residue, TRP4, showed strong van der Waals interactions to stabilize the ligands. Moreover, the average RMSD (Å) of lupeol-bound GLP-1R (3.45) are comparable to danuglipron-bound GLP-1R (3.33), indicating good stability in the pocket. This potentially situates lupeol as GLP-1R agonist similar to danuglipron, and thus opens up the opportunity for more further experimental work, to validate its agonist properties on GLP1R.